ReviewCurrent drug targets2012
Protein-protein interactions at the adrenergic receptors.
Review in Current drug targets, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Imbalance of Excitatory and Inhibitory Neurotransmitter Systems in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.International journal of molecular sciences · 2026Review
- The nature of sex differences in catecholamine-induced lipolysis in subcutaneous fat cells.iScience · 2025Article
- Norepinephrine protects against cochlear outer hair cell damage and noise-induced hearing loss via αBMC neuroscience · 2024Article
- Microvascular Capillary and Precapillary Cardiovascular Disturbances Strongly Interact to Severely Affect Tissue Perfusion and Mitochondrial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Evolving from the Post COVID-19 Syndrome.Medicina (Kaunas, Lithuania) · 2024Article
- Status of βReviews in cardiovascular medicine · 2023Review
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Comorbidities: Linked by Vascular Pathomechanisms and Vasoactive Mediators?Medicina (Kaunas, Lithuania) · 2023Article
- Dexmedetomidine Attenuates Lipopolysaccharide-Induced Sympathetic Activation and Sepsis via Suppressing Superoxide Signaling in Paraventricular Nucleus.Antioxidants (Basel, Switzerland) · 2022Article
- A Photoswitchable Ligand Targeting the βAngewandte Chemie (International ed. in English) · 2022Article
- Suppression of P2X3 receptor-mediated currents by the activation of αCNS neuroscience & therapeutics · 2022Article
- Central GαiFrontiers in endocrinology · 2022Review
- Toxoplasmosis: Targeting neurotransmitter systems in psychiatric disorders.Metabolic brain disease · 2022Review
- Co-Evolution of Opioid and Adrenergic Ligands and Receptors: Shared, Complementary Modules Explain Evolution of Functional Interactions and Suggest Novel Engineering Possibilities.Life (Basel, Switzerland) · 2021Article
- Astrocytes as Perspective Targets of Exercise- and Caloric Restriction-Mimetics.Neurochemical research · 2021Review
- Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).Journal of translational medicine · 2021Review
- The role of neutrophils in neuro-immune modulation.Pharmacological research · 2020Review
- Updates in the function and regulation of αBritish journal of pharmacology · 2019Review
- Fatigue, Sleep, and Autoimmune and Related Disorders.Frontiers in immunology · 2019Review
- Rediscovery of nefopam for the treatment of neuropathic pain.The Korean journal of pain · 2014Review
- Three basic residues of intracellular loop 3 of the beta-1 adrenergic receptor are required for golgin-160-dependent trafficking.International journal of molecular sciences · 2014Article
- Pannexin 1 in the regulation of vascular tone.Trends in cardiovascular medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adrenergic receptors are among the best characterized G protein-coupled receptors (GPCRs) and knowledge on this receptor family has provided several important paradigms about GPCR function and regulation. One of the most recent paradigms initially supported by studies on adrenergic receptors is that both βarrestins and G proteincoupled receptors themselves can act as scaffolds binding a variety of proteins and this can result in growing complexity of the receptor-mediated cellular effects. In this review we will briefly summarize the main features of βarrestin binding to the adrenergic receptor subtypes and we will review more in detail the main proteins found to selectively interact with distinct AR subtype. At the end, we will review the main findings on oligomerization of the AR subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.